Get the Stockscreener App
11.62
9.64%
-1.24
After Hours:
11.60
-0.02
-0.17%
Ars Pharmaceuticals Inc stock is traded at $11.62, with a volume of 7.18M.
It is down -9.64% in the last 24 hours and down -34.54% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$12.86
Open:
$12.7
24h Volume:
7.18M
Relative Volume:
4.36
Market Cap:
$1.15B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-24.72
EPS:
-0.47
Net Cash Flow:
$-44.23M
1W Performance:
-13.93%
1M Performance:
-34.54%
6M Performance:
+13.92%
1Y Performance:
-10.48%
1-Day Range:
$10.98
$12.70
1-Week Range:
$10.98
$14.00
52-Week Range:
$10.01
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Compare SPRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
11.62 | 1.27B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
Ranking ARS Pharmaceuticals Inc. among high performing stocks via toolsQuarterly Growth Report & Free Reliable Trade Execution Plans - Newser
Using data models to predict ARS Pharmaceuticals Inc. stock movementJuly 2025 Review & Entry Point Confirmation Alerts - Newser
What machine learning models say about ARS Pharmaceuticals Inc.Market Weekly Review & Daily Stock Trend Watchlist - Newser
Real time pattern detection on ARS Pharmaceuticals Inc. stockIPO Watch & Weekly Chart Analysis and Trade Guides - Newser
Is ARS Pharmaceuticals Inc. forming a bottoming baseLayoff News & Daily Growth Stock Investment Tips - Newser
What machine learning models say about ARS Pharmaceuticals Inc2025 Performance Recap & AI Powered Buy and Sell Recommendations - Newser
ARS Pharmaceuticals Inc. recovery potential after sell offEntry Point & Low Risk Entry Point Tips - Newser
Quantitative breakdown of ARS Pharmaceuticals Inc. recent moveTreasury Yields & Fast Entry Momentum Trade Alerts - Newser
Technical analysis overview for ARS Pharmaceuticals Inc. stockJuly 2025 Levels & Daily Oversold Bounce Ideas - Newser
How to interpret RSI for ARS Pharmaceuticals Inc. stockBull Run & Technical Entry and Exit Alerts - Newser
Custom watchlist performance reports with ARS Pharmaceuticals Inc.Market Risk Analysis & Growth Oriented Trade Recommendations - Newser
Price momentum metrics for ARS Pharmaceuticals Inc. explained2025 Support & Resistance & High Yield Stock Recommendations - Newser
What MACD and RSI say about ARS Pharmaceuticals Inc.Long Setup & Expert Verified Movement Alerts - Newser
Can ARS Pharmaceuticals Inc. rally from current levelsAnalyst Upgrade & Verified Swing Trading Watchlists - Newser
Custom watchlist performance reports with ARS Pharmaceuticals IncProfit Target & Daily Technical Forecast Reports - Newser
Risk vs reward if holding onto ARS Pharmaceuticals Inc.Oil Prices & Community Verified Trade Signals - Newser
Comparing ARS Pharmaceuticals Inc. in custom built stock radarsCEO Change & Verified Short-Term Plans - Newser
What recovery options are there for ARS Pharmaceuticals Inc.2025 Sector Review & Fast Moving Stock Watchlists - Newser
ARS Pharmaceuticals Faces Wider Loss in Q2, Stirring Market Concerns - StocksToTrade
Trading Bots Trigger Alerts on ARS Pharmaceuticals Inc. Activity getLinesFromResByArray error: size == 0 - thegnnews.com
ARS Pharmaceuticals Down 9% as Lupin Files Generic Neffy Application - AInvest
What the charts say about ARS Pharmaceuticals Inc. today2025 Biggest Moves & AI Driven Stock Reports - Newser
How high can ARS Pharmaceuticals Inc. stock go2025 Top Decliners & Short-Term Swing Trade Alerts - Newser
Applying Elliott Wave Theory to ARS Pharmaceuticals Inc.2025 Growth vs Value & Smart Allocation Stock Reports - Newser
Detecting price anomalies in ARS Pharmaceuticals Inc. with AIJuly 2025 Trade Ideas & Safe Entry Point Alerts - Newser
ARS Pharma drops 9% as Lupin files application for generic neffy - MSN
ARS Pharmaceuticals Faces Financial Struggles as Q2 Loss Exceeds Estimates - StocksToTrade
ARS Pharmaceuticals Plunges 8.7%—What Legal Storm Could Sink Neffy's Future? - AInvest
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):